Vivani Medical announced it has successfully completed the initial dosing of all 20 participants in its SLIM-1 Phase 1 clinical trial. The trial is evaluating NPM-139, the company's miniature, long-acting semaglutide implant for chronic weight management.
Key Details
- Trial Name: SLIM-1, a Phase 1, randomized, controlled trial comparing a low dose of the NPM-139 implant to the starting dose of Wegovy® (semaglutide injection).
- Objective: The 20-participant, four-week trial will assess the safety, tolerability, and pharmacokinetic profile of NPM-139 in overweight or obese individuals.
- Timeline: Dosing was completed ahead of schedule, and the company expects to report top-line data in November 2026, with plans to initiate a Phase 2 trial in 2027.